A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Trial Profile

A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2013

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; HIV protease inhibitors; Lamivudine/abacavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SWIFT
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 12 Oct 2011 Results presented at the 13th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top